• Mashup Score: 0

    The Society of Nuclear Medicine and Molecular Imagine (SNMMI) has called for clarity over whether amyloid PET scans will be covered for potential candidates for the new Alzheimer’s disease drug Leqembi (lecanemab).

    Tweet Tweets with this article
    • SNMMI calls for clarity over coverage for PET for patients on Leqembi https://t.co/uzi7lbQILe